<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87461">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02054351</url>
  </required_header>
  <id_info>
    <org_study_id>GM-IMAB-002-01</org_study_id>
    <secondary_id>2013-002755-15</secondary_id>
    <nct_id>NCT02054351</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)</brief_title>
  <acronym>OVAR</acronym>
  <official_title>A First-in-human Dose Escalation and Dose Finding Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ganymed Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ganymed Pharmaceuticals AG</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Ukraine: State Expert Center of Ministry of Health of Ukraine</authority>
    <authority>Russia: Federal Service on Surveillance in Healthcare and Social Development</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced ovarian cancer is a high medical need indication. Cure is not available to these
      patients and treatment has palliative intent. A proportion of advanced stage ovarian cancer
      expresses substantial levels of Claudin 6 (CLDN6), a carcino-embryonic transmembrane
      protein, which is absent from normal adult human tissue. IMAB027 is a monoclonal antibody
      that binds to CLDN6. Preclinically IMAB027 was shown to inhibit tumor growth and to kill
      cancer cells by antibody-dependent cellular cytotoxicity and complement-dependent
      cytotoxicity. This trial is a first-in-human dose escalation and dose finding phase 1/2
      trial of IMAB027 in patients with recurrent advanced ovarian cancer to assess the safety and
      tolerability, the pharmacokinetics, the antitumoral activity and the immunogenicity of
      IMAB027.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Frequency, severity, duration, type of adverse events</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Disease control rate according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1</measure>
    <time_frame>up to 32 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Disease Control Rate according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Frequency, severity, duration, type of adverse events</measure>
    <time_frame>up to 32 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression free survival, Objective response rate, Overall survival</measure>
    <time_frame>up to 32 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>IMAB027 administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMAB027</intervention_name>
    <description>Phase 1
Intrapatient dose escalation: 1 mg/m2, 10 mg/m2, 30 mg/m2, 100 mg/m2
Interpatient dose escalation: 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2</description>
    <arm_group_label>IMAB027 administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Female patients ≥18 years of age, no upper age limit.

          3. Histologically or cytologically confirmed CLDN6+ ovarian cancer of any histology type
             including primary peritoneal or fallopian tube tumors (histological documentation of
             the original primary tumor is required via a pathology report).

          4. Performance status ECOG 0-2

          5. Patients with measurable, non-measurable, or evaluable disease: Evaluable disease:
             defined as a confirmed CA-125 ≥2 x ULN, Measurable disease (RECIST 1.1): defined as
             at least one lesion that can be accurately measured in at least one dimension

          6. Availability of a FFPE tumor tissue sample for the assessment of CLDN6 positivity

          7. Life expectancy of &gt;12 weeks

          8. Adequate organ function defined as:

             Adequate hematologic function (ANC ≥1000/μl, platelets ≥100.000/μl, hemoglobin ≥9.0
             g/dl (can be post transfusion)) Adequate renal function (serum creatinine ≤1.5 mg/dl
             [114.5 μmol/l] or creatinine clearance rate ≥30 ml/min). Adequate liver function
             (serum total bilirubin ≤2 x ULN, AST/ALT ≤3 x ULN)

          9. Patients of child-bearing potential1 must have a negative β-HCG urine test within 72
             hours before receiving treatment

        Exclusion Criteria:

          1. Patient is pregnant or breast-feeding

          2. Prior allergic reaction or intolerance to a monoclonal antibody (humanized or
             chimeric)

          3. Any prior anti-tumor therapy within 14 days prior to the start of IMAB027 treatment

          4. Other concurrent anticancer therapies

          5. HIV infection in medical history or active Hepatitis B or C infection requiring
             treatment

          6. History of any one or more of the following cardiovascular conditions within the past
             6 months: Myocardial infarction (T-Wave/Non-T-Wave), Unstable angina pectoris Class
             II, III or IV congestive heart failure as defined by the New York Heart Association
             (NYHA), History of cerebrovascular accident, pulmonary embolism or untreated deep
             venous thrombosis (DVT). Patients with recent DVT who have been or are treated with
             therapeutic anti-coagulant agents (excluding warfarin) for at least 6 weeks are
             eligible

          7. Other investigational agents or devices concurrently or within 14 days before start
             of IMAB027 treatment.

          8. Any hemoptysis or bleeding event that is clinically relevant within 2 weeks of first
             dose of study drug

          9. Clinical symptoms of brain metastases or tumor-associated spinal cord compression.

         10. Need for continuous, systemic immunosuppressive therapy.

         11. Any other medical condition that would, in the opinion of the Investigator, limit the
             patient's ability to complete the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Jaeger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationales Zentrum für Tumorerkrankungen, Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angelika Schönfeld</last_name>
    <email>QA-GCP@ganymed.ag</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0032 24775459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Vergote, Prof. Dr.</last_name>
      <phone>0032 16344208</phone>
      <email>Ignace.Vergote@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Jäger, Prof. Dr.</last_name>
      <phone>0049 622 156 7229</phone>
      <email>dirk.jaeger@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Jäger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik (UFK) Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Brucker, Prof. Dr. med.</last_name>
      <phone>0049 707 129 807 91</phone>
      <email>sara.brucker@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Sara Brucker, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Frauenklinik</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Huober, Dr. med.</last_name>
      <phone>0049 731 500 58511</phone>
      <email>jens.huober@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Jens Huober, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Just, Dr. med.</last_name>
      <phone>0049 351 144 723 40</phone>
      <email>marianne.just@onkologie-bielefeld.de</email>
    </contact>
    <investigator>
      <last_name>Marianne Just, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Jacobasch, Dr. med.</last_name>
      <phone>0049 351 144 723 40</phone>
      <email>jacobasch@onkologie-dresden.net</email>
    </contact>
    <investigator>
      <last_name>Lutz Jacobasch, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced ovarian cancer</keyword>
  <keyword>CLDN6 positive</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
